Cell line · CVCL_1045
Papers217
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 217
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| In vivo validation of intramolecular bivalent glues targeting PSMA reveals potent and tissue-selective BRD4 degradation in prostate cancer. | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Obesity-Induced PLPE-PTK6-FASN Feedback Loop Drives Enzalutamide Resistance by Exacerbating Lipid Metabolic Dysregulation in Castration-Resistant Prostate Cancer. | Research (Wash D C) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Senolytic Interventions Enhance the Anti-metastatic Activity of Chemotherapy in Prostate Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Castration-resistant prostate cancer cells are addicted to the high activity of cyclin-dependent kinase 2. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SLPI is associated with AR-regulated epithelial adaptation and enzalutamide sensitivity in castration-resistant prostate cancer. | Front Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Vitronectin Enrichment in Prostate Cancer Liver Metastases Promotes Adhesion and Survival. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multi-omics dissection of FOXA1 reveals cancer-type-specific transcriptional networks and functional risk variants. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis. | Br J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Functional and omics-based rationale for the induction of BRCAness by androgen receptor pathway inhibitors to sensitize prostate cancer to PARP inhibition, regardless of HRR status. | Br J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lactate-induced H3K4me3 histone mark promotes PLOD1-driven prostate cancer invasion. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer. | J Clin Invest | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ERG Orchestrates a Dedifferentiation-Senescence-Inflammation Triad in Prostate Cancer. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Prevention of Myc-Driven Prostate Cancer in Mice by Oral Administration of Sulforaphane. | Mol Carcinog | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3-Directed and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Co-Targeting Nuclear Export and Translation Initiation Uncovers a Therapeutic Vulnerability in Lethal Prostate Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The YAP1-NPM1 nuclear complex regulates MYC and reveals a targetable oncogenic node. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly Expressed, Combinatorial Therapeutic Target. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| QW-5-70 Targets the Colchicine Site and Demonstrates Antitumor Activity in P-gp-Overexpressing Cancer Models. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Androgen Receptor-Induced Lactoferrin Accelerates Prostate Tumorigenesis Through Modulating Ferroptosis. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1045/papers